×
About 5,528 results

ALLMedicine™ Unstable Angina Center

Research & Reviews  1,453 results

Plasma Leukocyte Cell-Derived Chemotaxin 2 (LECT2) as a Risk Factor of Coronary Artery ...
https://doi.org/10.1177/00033197211028023
Angiology Wei M, Liu J et. al.

Jul 29th, 2021 - Many studies have shown that leukocyte cell-derived chemotaxin 2 (LECT2) is associated with metabolic disorders, which is a risk factor of arteriosclerosis. We assessed the level of LECT-2 in patients with coronary artery disease (CAD) and its sev...

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in pati...
https://doi.org/10.1177/2047487320902750
European Journal of Preventive Cardiology; Sever P, Gouni-Berthold I et. al.

Jul 24th, 2021 - Some trials have reported diminished efficacy for statins in the elderly, and in women compared with men. We examined the efficacy and safety of evolocumab by patient age and sex in the FOURIER trial, the first major cardiovascular outcome trial o...

Plasma Level of Elabela in Patients with Coronary Heart Disease and Its Correlation wit...
https://doi.org/10.1536/ihj.20-817
International Heart Journal; Tian QP, Liu ML et. al.

Jul 20th, 2021 - This study aimed to evaluate the concentration of plasma elabela (ELA) in patients with coronary heart disease (CHD) and its correlation with the disease classification.We enrolled 238 patients diagnosed by coronary angiography as CHD and 86 contr...

Early invasive versus non-invasive assessment in patients with suspected non-ST-elevati...
https://doi.org/10.1136/heartjnl-2020-318778
Heart (British Cardiac Society); Kite TA, Ladwiniec A et. al.

Jul 9th, 2021 - Non-ST-elevation acute coronary syndrome (NSTE-ACS) comprises a broad spectrum of disease ranging from unstable angina to myocardial infarction. International guidelines recommend a routine invasive strategy for managing patients with NSTE-ACS at ...

see more →

Guidelines  5 results

What's new in antiplatelet and anticoagulant therapy recommendations for unstable angin...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652660
Clinical Cardiology; Wenger NK,

Oct 17th, 2012 - This focused update addresses the use of the newly approved oral antiplatelet agents, prasugrel and ticagrelor, for the management of patients with UA/NSTEMI.

2012 Oman Heart Association simplified guidelines for the management of patients with u...
https://doi.org/10.1097/HPC.0b013e31825ac653
Critical Pathways in Cardiology; El-Deeb MH, Al Riyami AM et. al.

Jul 25th, 2012 - Although current practice guidelines provide an evidence-based approach to the management of acute coronary syndromes, application of the evidence by individual physicians has been suboptimal. This gap between comprehensive guidelines and actual p...

2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Mana...
https://doi.org/10.1016/j.jacc.2011.02.011
Journal of the American College of Cardiology; Wright RS, Anderson JL et. al.

May 7th, 2011 - 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Associa...

2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Mana...
https://doi.org/10.1161/CIR.0b013e318212bb8b
Circulation Anderson JL, Adams CD et. al.

Mar 30th, 2011 - 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Associa...

Early management of unstable angina and non-ST segment elevation myocardial infarction:...
https://doi.org/10.1136/bmj.c1134
BMJ (Clinical Research Ed.); Crowe E, Lovibond K et. al.

Mar 26th, 2010 - Early management of unstable angina and non-ST segment elevation myocardial infarction: summary of NICE guidance.|2010|Crowe E,Lovibond K,Gray H,Henderson R,Krause T,|therapy,therapeutic use,therapy,diagnosis,therapeutic use,diagnosis,

see more →

Drugs  232 results see all →

Clinicaltrials.gov  124 results

Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury
https://clinicaltrials.gov/ct2/show/NCT03236441

Apr 6th, 2020 - The BRICK study is a prospective, double-blind, sham-controlled, randomized clinical trial in patients with non-ST elevation myocardial infarction and unstable angina undergoing cardiac catheterization and percutaneous coronary intervention who ar...

Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal...
https://clinicaltrials.gov/ct2/show/NCT03666832

Dec 30th, 2019 - Inclusion Subjects who are males or females ≥ 19 years of age Subjects who have the following history of first-line gemcitabine and nab-paclitaxel among patients with cytologically or histologically proven metastatic pancreatic ductal adenocarcino...

Evolution of Cardiovascular Function and Quality of Life in Patients Included in the SCArabée Therapeutic Education Program
https://clinicaltrials.gov/ct2/show/NCT03669211

Jul 30th, 2019 - Coronary artery disease is defined as a disease of the arteries that vascularize the heart, resulting in myocardial ischemia, i.e. insufficient blood supply to the heart muscle. Eventually, it may be responsible for acute coronary syndrome that in...

Multiomics and Imaging-based Assessment of Vulnerable Coronary Plaques in Acute Coronary Syndromes
https://clinicaltrials.gov/ct2/show/NCT03391908

Jul 30th, 2019 - This is a prospective cohort monocentric study. The primary objective of this study is to research the vulnerability degree of ateromatous plaques before and after a myocardial infarction, based on multiomics data, invasive and non-invasive imagin...

ALLiance for sEcondary PREvention After an Episode of Acute Coronary Syndrome (ALLEPRE)
https://clinicaltrials.gov/ct2/show/NCT02522182

Jul 19th, 2019 - ALLEPRE enrols a population of residents in Emilia Romagna with a diagnosis of ACS (unstable angina, non-ST segment elevation myocardial infarction, ST segment elevation myocardial infarction) who were admitted to the specialist cardiological depa...

see more →

News  394 results

Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings | FDA
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-enoxaparin-sodium-injection-usp-due-mislabeling

Summary Company Announcement Date: February 02, 2021 FDA Publish Date: February 03, 2021 Product Type: Drugs Reason for Announcement: Recall Reason Description Packaging error resulting in incorrect dosage listed Company Name: Apotex Corp Brand Na...

CV Benefit of Eicosapentaenoic Acid Seen at All eGFR Levels
https://www.staging.medscape.com/viewarticle/939867

Oct 27th, 2020 - Daily icosapent ethyl (Vascepa) safely and effectively reduces fatal and nonfatal ischemic events in patients with reduced kidney function, a prespecified analysis of the REDUCE-IT RENAL study shows. "Some cardiovascular drugs are not as effective...

Once Again, No Survival Benefit With PCI, Surgery in Stable CAD
https://www.medscape.com/viewarticle/933211

Jun 30th, 2020 - Coronary revascularization does not confer a survival advantage over initial medical therapy in patients with stable ischemic heart disease (SIHD) but reduces unstable angina, according to a new study-level meta-analysis. Routine upfront revascula...

Once Again, No Survival Benefit With PCI, Surgery in Stable CAD
https://www.staging.medscape.com/viewarticle/933211

Jun 30th, 2020 - Coronary revascularization does not confer a survival advantage over initial medical therapy in patients with stable ischemic heart disease (SIHD) but reduces unstable angina, according to a new study-level meta-analysis. Routine upfront revascula...

REDUCE-IT: CV Benefit of Icosapent Ethyl Directly Related to EPA Levels
https://www.medscape.com/viewarticle/928019

Apr 2nd, 2020 - The reduction in cardiovascular (CV) events seen in the REDUCE-IT trial with icosapent ethyl (Vascepa, Amarin), a high-strength formulation of purified eicosapentaenoic acid (EPA), were directly related to on-treatment serum levels of EPA, and not...

see more →

Patient Education  3 results see all →